PMID- 30790057
OWN - NLM
STAT- MEDLINE
DCOM- 20190422
LR  - 20200516
IS  - 1432-1831 (Electronic)
IS  - 0300-8584 (Linking)
VI  - 208
IP  - 2
DP  - 2019 Apr
TI  - Conserved peptide vaccine candidates containing multiple Ebola nucleoprotein 
      epitopes display interactions with diverse HLA molecules.
PG  - 227-238
LID - 10.1007/s00430-019-00584-y [doi]
AB  - Immunoinformatics has come by leaps and bounds to finding potent vaccine 
      candidates against various pathogens. In the current study, a combination of 
      different T (CD4(+) and CD8(+)) and B cell epitope prediction tools was applied 
      to find peptides containing multiple epitopes against Ebola nucleoprotein (NP) 
      and the presentation of peptides to human leukocyte antigen (HLA) molecules was 
      analyzed by prediction, docking and population coverage tools. Further, potential 
      peptides were analyzed by ELISA for peptide induced IFN-gamma secretion in peripheral 
      blood mononuclear cells isolated from healthy volunteers. Six peptides were 
      obtained after merging the overlapping multiple HLA I (CD8(+)) and II (CD4(+)) 
      restricted T cell epitopes as well as B cell epitopes and eliminating the 
      peptides liable to generate autoimmune and allergic response. All peptides 
      displayed 100% conservancy in Zaire ebolavirus. In other Ebola virus species 
      (Sudan, Bundibugyo and Tai forest) and Filoviridae members (Lloviuvirus and 
      Margburgvirus), some peptides were found to be conserved with minor variations. 
      Prediction tools confirmed the ability of predicted peptides to bind with diverse 
      HLA (HLA-A, HLA-B, HLA-DP, HLA-DQ and HLA-DR) alleles. CABS-dock results 
      displayed that the average root mean square deviation (RMSD) value was less than 
      three in majority of cases representing strong binding affinity with HLA alleles. 
      Population coverage analysis predicted high coverage (> 85%) for expected immune 
      response in four continents (Africa, America, Asia and Europe). Nine out of ten 
      blood samples exhibited enhanced IFN-gamma secretion for two peptides (P2 and P3). 
      Thus, the identified NP peptides can be considered as potential synthetic vaccine 
      candidates against Ebola virus.
FAU - Jain, Sahil
AU  - Jain S
AD  - Department of Biotechnology, Thapar Institute of Engineering and Technology, 
      Patiala, Punjab, 147004, India.
FAU - Baranwal, Manoj
AU  - Baranwal M
AUID- ORCID: 0000-0002-6581-9346
AD  - Department of Biotechnology, Thapar Institute of Engineering and Technology, 
      Patiala, Punjab, 147004, India. manoj.baranwal@thapar.edu.
LA  - eng
GR  - NA/This research did not receive any specific grant from funding agencies in the 
      public, commercial or not-for-profit sectors./
PT  - Journal Article
DEP - 20190221
PL  - Germany
TA  - Med Microbiol Immunol
JT  - Medical microbiology and immunology
JID - 0314524
RN  - 0 (Antigens, Viral)
RN  - 0 (Ebola Vaccines)
RN  - 0 (Epitopes)
RN  - 0 (HLA Antigens)
RN  - 0 (Nucleoproteins)
RN  - 0 (Vaccines, Subunit)
RN  - 82115-62-6 (Interferon-gamma)
SB  - IM
MH  - Antigens, Viral/genetics/immunology
MH  - Computational Biology
MH  - Ebola Vaccines/genetics/*immunology
MH  - Ebolavirus/genetics/*immunology
MH  - Epitopes/genetics/*immunology
MH  - HLA Antigens/genetics/*metabolism
MH  - Healthy Volunteers
MH  - Hemorrhagic Fever, Ebola/*prevention & control
MH  - Humans
MH  - Interferon-gamma/metabolism
MH  - Leukocytes, Mononuclear/*immunology
MH  - Nucleoproteins/genetics/*immunology
MH  - Vaccines, Subunit/genetics/immunology
OTO - NOTNLM
OT  - Conservation analysis
OT  - Ebola nucleoprotein
OT  - Epitope-based vaccine
OT  - HLA alleles
OT  - Molecular docking
EDAT- 2019/02/23 06:00
MHDA- 2019/04/23 06:00
CRDT- 2019/02/22 06:00
PHST- 2018/09/18 00:00 [received]
PHST- 2019/02/11 00:00 [accepted]
PHST- 2019/02/23 06:00 [pubmed]
PHST- 2019/04/23 06:00 [medline]
PHST- 2019/02/22 06:00 [entrez]
AID - 10.1007/s00430-019-00584-y [pii]
AID - 10.1007/s00430-019-00584-y [doi]
PST - ppublish
SO  - Med Microbiol Immunol. 2019 Apr;208(2):227-238. doi: 10.1007/s00430-019-00584-y. 
      Epub 2019 Feb 21.